Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.

Hanna N, Lilenbaum R, Ansari R, Lynch T, Govindan R, Jänne PA, Bonomi P.

J Clin Oncol. 2006 Nov 20;24(33):5253-8.

PMID:
17114658
2.

Cetuximab in advanced non-small cell lung cancer.

Govindan R.

Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4241s-4244s. Review.

3.

Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: a systematic review and meta-analysis.

Lin H, Jiang J, Liang X, Zhou X, Huang R.

Lung Cancer. 2010 Oct;70(1):57-62. doi: 10.1016/j.lungcan.2010.01.009. Epub 2010 Feb 10. Review.

PMID:
20149474
4.

The evolving role of cetuximab in non-small cell lung cancer.

Lilenbaum RC.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4432s-4435s. Review.

5.

[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].

Reck M, Kranich AL, Steinbach AK, Gatzemeier U.

Med Klin (Munich). 2005 Dec 15;100(12):785-93. Review. German.

PMID:
16453093
6.

Cetuximab in non-small-cell lung cancer.

Carillio G, Montanino A, Costanzo R, Sandomenico C, Piccirillo MC, Di Maio M, Daniele G, Giordano P, Bryce J, Normanno N, Rocco G, Perrone F, Morabito A.

Expert Rev Anticancer Ther. 2012 Feb;12(2):163-75. doi: 10.1586/era.11.178. Review.

PMID:
22316364
7.

Erlotinib as a single agent in select subsets of patients with advanced non-small-cell lung cancer.

Carrión RP, Gracián AC, Hernandez PS.

Clin Lung Cancer. 2007 Jul;8(7):425-8. Review.

PMID:
17681095
8.

Cetuximab in non-small cell lung cancer.

Ademuyiwa FO, Hanna N.

Expert Opin Biol Ther. 2008 Jan;8(1):107-13. Review.

PMID:
18081540
9.

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials.

Sheng J, Yang YP, Zhao YY, Qin T, Hu ZH, Zhou T, Zhang YX, Hong SD, Ma YX, Zhao HY, Huang Y, Zhang L.

Medicine (Baltimore). 2015 Aug;94(34):e1400. doi: 10.1097/MD.0000000000001400. Review.

10.

Cetuximab in advanced non-small cell lung cancer.

Rossi A, Maione P, Gridelli C.

Crit Rev Oncol Hematol. 2006 Aug;59(2):139-49. Epub 2006 Jun 23. Review.

PMID:
16806963
11.
12.

Efficacy of fourth-line chemotherapy in advanced non-small-cell lung cancer: a systematic review and pooled analysis of published studies.

Petrelli F, Coinu A, Cabiddu M, Borgonovo K, Ghilardi M, Lonati V, Barni S.

Anticancer Drugs. 2015 Sep;26(8):807-12. doi: 10.1097/CAD.0000000000000252. Review.

PMID:
26020807
13.

["Targeted Therapies" in NSCLC - present and future].

Pall G, Hilbe W.

Wien Med Wochenschr. 2007;157(21-22):545-53. Review. German.

PMID:
18157592
14.

Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review.

Hoag JB, Azizi A, Doherty TJ, Lu J, Willis RE, Lund ME.

J Exp Clin Cancer Res. 2009 Aug 14;28:113. doi: 10.1186/1756-9966-28-113. Review.

Supplemental Content

Support Center